Merck & Co Inc at Jefferies Global Healthcare Conference in New York Transcript
Good morning, everyone. Still morning? Yes, it is still in the morning.
My name's Akash Tewari. I head our pharma and biotech efforts here on the research side for Jefferies.
Joining us is Merck, a company that really global company with focus on multiple disease areas, but we have Marjorie who heads their Oncology efforts and Merck is certainly a leader there and we're fresh from coming from ASCO. So I'm really excited for this conversation.
Marjorie, maybe I'll hand it off to you for some opening remarks and we'll get to going.
Yeah, no, great. Thanks so much. I -- ASCO was an exciting time for Merck and for us. Our partners, Kelun-Biotech presented data from OptiTROP-Lung05, which is a Phase 3 global study looking in non-small cell lung cancer at the combination of sac-TMT combined with KEYTRUDA versus KEYTRUDA alone showing clinically meaningful improvements in progression-free
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
